Beam Therapeutics

We’re thrilled to have our new class of co-ops join the #BeamTeam! Read their quotes to learn why they chose Beam and what they’re looking forward to during their time here. We can’t wait to see you all #DaretoBeam!🎉

The #BeamTeam in Cambridge, MA took a break from the heat this week to enjoy the summer breeze and sunshine on the Charles River. A fun way to connect with our colleagues and cool off! #DareToBeam #TeamOuting #CharlesRiver #CambridgeMA

The #BeamTeam is growing! Want to be a part of our mission to advance science with the potential to save lives? We’re hiring across multiple departments in Cambridge and North Carolina. Explore our open positions and help us break new ground: beamtx.com/jobs

The #BeamTeam had a great time celebrating #Pride this month by hosting tie dye events in Cambridge and North Carolina, walking in the Boston Pride Parade, and participating in the OUT! Raleigh Pride Festival. We’re proud to be powered by difference. #DaretoBeam

We're happy to share that the Beam Summer Blast was, in fact, a blast! The Cambridge #BeamTeam, along with family & friends, came together at the @museumofscience. What a way to kick off summer and celebrate our 8-year anniversary as a company! #DaretoBeam

The #BeamTeam is growing! We're hiring across many functions at our Cambridge and North Carolina locations. Check out our open roles and #DaretoBeam: beamtx.com/jobs/

We’re thrilled to welcome our newest class of interns to the #BeamTeam! We’re excited to see the impact you’ll make and can’t wait to see how you #DaretoBeam this summer.

As our co-ops wrap up their time with us, they shared their capstone presentations with the #BeamTeam to showcase their innovative work. Thank you all for your contributions and fresh perspectives, and we look forward to seeing your continued accomplishments! #DaretoBeam

Today, we announced that the US FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). Read the full press release here: investors.beamtx.com/news-releases/… #DaretoBeam #BeamTeam

Today, we announced that the United States Food and Drug Administration has granted orphan drug designation to BEAM-302. Read the full press release here: investors.beamtx.com/news-releases/… #DaretoBeam #BeamTeam